Case report
Open access
Oct 2026
Iptacopan combined with immunosuppressive therapy for aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome
Iptacopan served as a bridge to control hemolysis, while the subsequent addition of IST addressed the underlying autoimmune bone marrow failure and no breakthrough hemolysis, extravascular hemolysis, or drug-related adverse events were observed.
Xiao-Qian Liu, Jie Xu, Ya-Qin Luo et al.
· Medicine · 0 citations